275 Results

People

  1. Levine
    Levine
  2. Abdel-Wahab
    Abdel-Wahab
  3. Scheinberg
    Scheinberg
  4. Clarkson
    Clarkson
  5. Berman
    Berman
  6. Giralt
    Giralt
  7. Mauro
    Mauro
  8. Tallman
    Tallman
  9. Warrell
    Warrell
  10. Patel
    Patel

Groups

  1. Department of Medicine (189)
  2. Hematologic Malignancies, Division of (183)
  3. Center for Hematologic Malignancies (176)
  4. Adult Leukemia (108)
  5. GSK Faculty (94)
  6. Tow Center for Developmental Oncology (TCDO) (66)
  7. Sloan Kettering Institute Faculty (59)
  8. Executive Committee, Center for Hematologic Malignancies (57)
  9. Molecular Pharmacology and Chemistry Program Faculty (41)
  10. Center for Molecular Imaging and Biotechnology (40)
  1. "Leukemia"
Formats
  1. Journal Article (218)
  2. Research Letter (25)
  3. Review (11)
  4. Conference Paper (8)
  5. Meeting Abstract (6)
  6. Correspondence (4)
  7. Editorial (3)
Groups
  1. Department of Medicine (189)
  2. Hematologic Malignancies, Division of (183)
  3. Center for Hematologic Malignancies (176)
  4. Adult Leukemia (108)
  5. GSK Faculty (94)
  6. Tow Center for Developmental Oncology (TCDO) (66)

More Groups

People
  1. Ross Levine (34)
  2. Omar Abdel-Wahab (29)
  3. Bayard Clarkson (18)
  4. David Scheinberg (18)
  5. Martin Tallman (17)
  6. Ellin Berman (11)

More People

Years
  1. 2025 (11)
  2. 2024 (14)
  3. 2023 (14)
  4. 2022 (18)
  5. 2021 (26)
  6. 2020 (10)

More Years

Publications
  1. Leukemia (275)
Publishers
  1. Nature Publishing Group (275)

Results (275)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: Phase 1 study final results
    Journal Article

    Cortes, J. E.; Lang, F.; Rea, D.; Hochhaus, A.; Breccia, M.; Goh, Y. T.; Heinrich, M. C.; Hughes, T. P.; Janssen, J. J. W. M.; le Coutre, P.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: An International Myeloma Foundation immunotherapy database real-world analysis: IMMUNOTHERAPY
    Correspondence

    Mian, H.; Martin, T. G.; Pond, G. R.; Asoori, S.; Popat, R.; Kastritis, E.; Martinez-Lopez, J.; Abdallah, N.; Chhabra, S.; Parrondo, R.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results: CHRONIC MYELOID LEUKEMIA
    Journal Article

    Hochhaus, A.; Kim, D. W.; Cortes, J. E.; Sasaki, K.; Mauro, M. J.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
    Journal Article

    Shah, B. D.; Cassaday, R. D.; Park, J. H.; Houot, R.; Logan, A. C.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; O’Dwyer, K. M.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Urine-free response criteria predict progression-free survival in multiple myeloma: A post hoc analysis of BMT CTN 0702
    Research Letter

    Banerjee, R.; Fritz, A. R.; Akhtar, O. S.; Freeman, C. L.; Cowan, A. J.; Shah, N.; Landau, H. J.; Kumar, S. K.; Vogl, D. T.; Efebera, Y. A.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes: MULTIPLE MYELOMA, GAMMOPATHIES
    Journal Article

    Facon, T.; Moreau, P.; Weisel, K.; Goldschmidt, H.; Usmani, S. Z.; Chari, A.; Plesner, T.; Orlowski, R. Z.; Bahlis, N.; Basu, S.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Phase 1 clinical trial of B-cell maturation antigen (BCMA) NEX-T® chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
    Journal Article

    Ravi, G.; Richard, S.; Kumar, S.; Atrash, S.; Liedtke, M.; Kaur, G.; Derman, B.; Bergsagel, P. L.; Mailankody, S.; McCarthy, P.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
    Research Letter

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A.; Sallman, D.; Patel, M.; Stevens, D.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: Analysis of key subgroups of the MAIA study
    Journal Article

    Moreau, P.; Facon, T.; Usmani, S. Z.; Bahlis, N.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms
    Correspondence

    Salmon-Divon, M.; Meyuchas, R.; Shpilberg, O.; Okon, E.; Benhamida, J.; Yabe, M.; Petrova-Drus, K.; Zvida-Bloch, T.; Basood, M.; Mazor, R.; more...
    Leukemia (2025)

    Fulltext@MSK | Save